Nomura Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26.4M Sell
42,310
-11,624
-22% -$7.91M 0.06% 293
2026
Q1
$41.7M Buy
53,934
+517
+1% +$396K 0.11% 201
2025
Q4
$41.2M Sell
53,417
-374
-0.7% -$254K 0.1% 206
2025
Q3
$30.2M Sell
53,791
-2,223
-4% -$1.26M 0.08% 247
2025
Q2
$29.4M Sell
56,014
-37,278
-40% -$20.8M 0.08% 258
2025
Q1
$59.2M Buy
93,292
+778
+0.8% +$535K 0.18% 129
2024
Q4
$65.9M Buy
92,514
+6,510
+8% +$5.46M 0.2% 111
2024
Q3
$90.4M Buy
86,004
+3,698
+4% +$4.12M 0.28% 80
2024
Q2
$86.5M Buy
82,306
+6,978
+9% +$6.76M 0.29% 72
2024
Q1
$72.5M Buy
75,328
+16,405
+28% +$15.6M 0.26% 82
2023
Q4
$51.8M Buy
58,923
+1,439
+3% +$1.19M 0.21% 114
2023
Q3
$47.3M Buy
57,484
+1,671
+3% +$1.31M 0.22% 108
2023
Q2
$40.1M Sell
55,813
-1,556
-3% -$1.2M 0.18% 128
2023
Q1
$47.1M Sell
57,369
-9,684
-14% -$7.3M 0.25% 96
2022
Q4
$48.4M Sell
67,053
-2,159
-3% -$1.59M 0.28% 84
2022
Q3
$47.7M Sell
69,212
-5,034
-7% -$3.17M 0.3% 74
2022
Q2
$43.9M Buy
74,246
+14,676
+25% +$9.54M 0.27% 84
2022
Q1
$41.6M Buy
59,570
+1,817
+3% +$1.15M 0.23% 98
2021
Q4
$36.5M Buy
57,753
+3,409
+6% +$2.1M 0.18% 119
2021
Q3
$32.9M Sell
54,344
-11,836
-18% -$7.35M 0.19% 120
2021
Q2
$37M Sell
66,180
-2,253
-3% -$1.14M 0.21% 111
2021
Q1
$32.4M Buy
68,433
+9,818
+17% +$4.78M 0.21% 109
2020
Q4
$28.3M Buy
58,615
+7,283
+14% +$3.93M 0.19% 117
2020
Q3
$28.7M Buy
51,332
+2,873
+6% +$1.74M 0.22% 100
2020
Q2
$30.2M Buy
48,459
+23,358
+93% +$13.3M 0.26% 88
2020
Q1
$12.3M Sell
25,101
-941
-4% -$388K 0.13% 167
2019
Q4
$9.78M Buy
26,042
+2,123
+9% +$714K 0.09% 228
2019
Q3
$6.63M Buy
23,919
+2,894
+14% +$856K 0.06% 280
2019
Q2
$6.58M Sell
21,025
-124,395
-86% -$41.4M 0.07% 266
2019
Q1
$59.7M Buy
145,420
+128,551
+762% +$52.9M 0.59% 37
2018
Q4
$6.3M Sell
16,869
-459
-3% -$168K 0.07% 246
2018
Q3
$7M Sell
17,328
-1,126
-6% -$429K 0.07% 246
2018
Q2
$6.37M Buy
18,454
+516
+3% +$161K 0.07% 250
2018
Q1
$6.18M Buy
17,938
+436
+2% +$152K 0.07% 250
2017
Q4
$6.58M Buy
17,502
+492
+3% +$199K 0.08% 231
2017
Q3
$7.61M Buy
17,010
+151
+0.9% +$71.9K 0.1% 198
2017
Q2
$8.28M Buy
16,859
+621
+4% +$272K 0.11% 186
2017
Q1
$6.29M Buy
16,238
+229
+1% +$84.9K 0.09% 229
2016
Q4
$5.88M Sell
16,009
-1,369
-8% -$521K 0.11% 219
2016
Q3
$6.99M Buy
17,378
+1,827
+12% +$733K 0.13% 190
2016
Q2
$5.43M Sell
15,551
-3,367
-18% -$1.3M 0.1% 210
2016
Q1
$6.82M Buy
18,918
+6,881
+57% +$2.84M 0.13% 178
2015
Q4
$6.54M Sell
12,037
-528
-4% -$286K 0.13% 183
2015
Q3
$5.84M Buy
12,565
+347
+3% +$186K 0.12% 193
2015
Q2
$6.23M Sell
12,218
-287
-2% -$140K 0.12% 182
2015
Q1
$5.65M Buy
12,505
+266
+2% +$113K 0.1% 200
2014
Q4
$5M Sell
12,239
-125
-1% -$49.2K 0.09% 226
2014
Q3
$4.46M Buy
12,364
+706
+6% +$237K 0.08% 236
2014
Q2
$3.29M Buy
11,658
+636
+6% +$188K 0.06% 288
2014
Q1
$3.31M Sell
11,022
-1,513
-12% -$466K 0.06% 286
2013
Q4
$3.45M Buy
12,535
+630
+5% +$181K 0.06% 279
2013
Q3
$3.73M Buy
11,905
+14
+0.1% +$3.68K 0.07% 262
2013
Q2
$2.67M Buy
+11,891
New +$2.77M 0.05% 345

Other funds holding REGN

Nomura Asset Management's REGN Position: Q2 2026 in Review

Nomura Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 22% in Q2 2026, selling an estimated $7.91M and leaving 42,310 shares worth $26.4M. The position accounts for 0.06% of the portfolio, ranked #293.

Nomura Asset Management first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $90.4M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Nomura Asset Management held 42,310 shares of Regeneron Pharmaceuticals worth $26.4M as of Q2 2026.
  • Nomura Asset Management sold 11,624 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $7.91M.
  • Regeneron Pharmaceuticals made up 0.06% of Nomura Asset Management's portfolio in Q2 2026, its #293 holding.
  • Nomura Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Nomura Asset Management's Regeneron Pharmaceuticals position peaked at $90.4M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.